EUVIMEDEUVIMED entdecken
Crossref

Psoriatic Patients with Cancer: A Multicentric Real-Life Study Comparing Risankizumab and Apremilast

Annunziata Raimondo, Anna Balato, Claudio Guarneri, Luigi Ligrone, Raffaella Manzo, Matteo Megna, Maria Letizia Musumeci, Giovanni Palazzo, Rosa Valentina Puca, Francesca Romano, Serena Lembo

Dermatology · 05.08.2026 · 1-6

DOI: 10.1159/000553458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology, online erschienen am 05.08.2026. Verfasst von Annunziata Raimondo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Salerno, Italy, araimondo@unisa.it. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: Evidence on the management of psoriasis in patients with a recent history of malignancy is limited, and safety data on systemic and biologic therapies in this setting are very important. Recent studies confirm the safety of anti-interleukin (IL) biological drugs in patients with psoriasis and a personal history of cancer. This report presents the safety and effectiveness assessments of risankizumab (RISA) and apremilast (APRE) in psoriatic patients with a recent cancer diagnosis (

Schlagwörter

Stichwörter der Autor:innen

ApremilastCancerPsoriasisRisankizumab

Autor:innen und Institutionen

  • Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Salerno, Italy, araimondo@unisa.it.
  • Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Dermatology, University of Messina, Messina, Italy.
  • Dermatology Unit, San Giovanni di Dio e Ruggi D'Aragona University Hospital, Salerno, Italy.
  • Dermatology Unit, A. Tortora Hospital, Pagani, Italy.
  • Section of Dermatology, Department of Clinical, Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Zitieren

APA

Raimondo, A., Balato, A., Guarneri, C., Ligrone, L., Manzo, R., Megna, M., Musumeci, M. L., Palazzo, G., Puca, R. V., Romano, F., & Lembo, S. (2026). Psoriatic Patients with Cancer: A Multicentric Real-Life Study Comparing Risankizumab and Apremilast. Dermatology, 1-6. https://doi.org/10.1159/000553458

Vancouver

Raimondo A, Balato A, Guarneri C, Ligrone L, Manzo R, Megna M, et al. Psoriatic Patients with Cancer: A Multicentric Real-Life Study Comparing Risankizumab and Apremilast. Dermatology. 2026:1-6. doi:10.1159/000553458

BibTeX
@article{Raimondo2026,
  author = {Raimondo, Annunziata and Balato, Anna and Guarneri, Claudio and Ligrone, Luigi and Manzo, Raffaella and Megna, Matteo and Musumeci, Maria Letizia and Palazzo, Giovanni and Puca, Rosa Valentina and Romano, Francesca and Lembo, Serena},
  title = {Psoriatic Patients with Cancer: A Multicentric Real-Life Study Comparing Risankizumab and Apremilast},
  journal = {Dermatology},
  year = {2026},
  pages = {1--6},
  doi = {10.1159/000553458}
}
Kostenlos starten →